This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Langer CJ , Leighton JC , Comis RL , Odwyer PJ , McAleer CA , Bonjo CA , Engstrom PF , Litwin S , Ozols RF
Paclitaxel and Carboplatin in Combination in the Treatment of Advanced Non-Small-Cell Lung-Cancer - a Phase-Ii Toxicity, Response, and Survival Analysis
Journal of Clinical Oncology. 1995 Aug;13(8) :1860-1870
AbstractPurpose: To determine the activity and toxicity of combination paclitaxel (24 hours) and carboplatin in advanced non-small- cell lung cancer (NSCLC). Patients and Methods: Eligibility required measurable disease (stage IV or stage IIB with malignant pleural effusion), Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, absolute neutrophil count greater than or equal to 2,000/mu L, platelet count greater than or equal to 100,000/mu L serum creatinine concentration less than or equal to 1.5 mg/dL, and bilirubin level less than or equal to 2 mg/dL. Paclitaxel was initially administered at a dose of 135 mg/m(2)/d, followed by carboplatin on day 2 at a targeted area under the concentration-time curve (AUG) of 7.5 using the Calvert formula. Granulocyte colony-stimulating factor (G-CSF) 5 mu g/kg subcutaneously (SC) on days 3 to 17 was introduced during the second and subsequent cycles. In patients who sustained less than grade 4 myelosuppression, the paclitaxel dose was sequentially escalated 40 mg/m(2) per cycle to a maximum of 215 mg/m(2). Treatment was repeated at 3-week intervals for six cycles. Results: From June 1993 through February 1994, 54 patients were enrolled; 53 are assessable for toxicity and response. The median age was 62 years (range, 34 to 84). Sixty-nine percent were male, 65% had adenocarcinoma, and 93% had stage IV disease. Two hundred sixty-eight cycles were administered; 32 patients (59%) completed all six cycles. Twenty-five unanticipated hospitalizations occurred during treatment (9.3% of cycles) in 20 patients (37%). Myelosuppression was the principal toxicity; grade 3 or 4 granulocytopenia occurred in 57% of patients after the first cycle, but decreased to 35% during the second cycle after introduction of G-CSP and consistently remained less than or equal to 22% during subsequent cycles. Seven episodes of neutropenic fever occurred, all during the first cycle. Grade 3 or 4 thrombocytopenia and anemia occurred in 47% and 33% of patients, respectively. Eight patients (15%) required platelet transfusions and 16(30%) required packed RBC support. Neuropathy, my algias/arthralgias, and thrombocytopenia, although generally mild, were cumulative. The paclitaxel dose wets boosted to 215 mg/m(2) in greater than or equal to 70% of patients who received three or more cycles. Ar an AUC of 7.5, the median first-cycle carboplatin dose was 424 mg/m(2) (range, 273 to 709 mg/m(2)). The objective response rate was 62%, with five (9%) complete responses and 28 (53%) partial responses. The median progression-free survival time was 28 weeks and the median survival time 53 weeks. The 1-year survival rate is 54%. Conclusion: The paclitaxel-carboplatin combination is active in advanced NSCLC and may enhance survival; it merits further investigation in phase III trials. J Clin Oncol 13:1860-1870. (C) 1995 by American Society of Clinical Oncology.
NotesTimes Cited: 230 Article RM473 J CLIN ONCOL